Amniocentesis test > amniocentesis test down syndrome > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Amniocentesis test

Non-Invasive Prenatal Test (NIPT) For Trisomy Detects Risks Early and Safely

Testing for potential fetal abnormalities is recommended for all expectant parents. Most commonly, when trisomy syndrome screening is prescribed, it is carried out through an amniocentesis test. But this procedure is not without risk: while the chances of losing the fetus is are small, it remains a concern. In response, Biomnis has developed non-invasive prenatal tests (NIPTs) that offer fast and accurate results. The easy-to-administer kits draws genetic analysis from a maternal blood sample. By choosing NIPT screening over amniocentesis tests in a first instance, it can be safely determined whether the risk of fetal defects is high or low, reducing the need for invasive procedures by up to 95%.

When assessing whether traditional amniocentesis tests for trisomy are worth potential complications and risks, expectant parents can find themselves facing a difficult dilemma. Luckily, there are now safer alternatives that offer close to 100% accurate risk assessment. Non-invasive genetic testing during pregnancycan be a good option for pregnant women at risk of fetal Patau syndrome, Edward's Syndrome, or Down syndrome. The non-invasive prenatal tests developed byEurofins Biomnis effectively detect trisomy 13, 18 and 21, and can be carried out by your healthcare provider. Available starting from only the 10th week of pregnancy, they represent a good first step before considering amniocentesis tests for trisomy.

The prenatal Down Syndrome screening kits developed by Eurofins Biomnis represent an effective alternative to invasive procedures, including amniocentesis tests for Down Syndrome. Aside from maternal DNA, the blood of pregnant women contains fetal DNA originating from the placenta. The identification of fetal DNA in the maternal blood sample, in tandem with a new technology called Next Generation Sequencing that is capable of counting all genetic material sequences in the sample, permits the rapid and accurate detection of trisomy-related abnormalities. With a more than 99% detection rate, this innovative option may allow you to limit or entirely forgo potentially risky procedures such as amniocentesis tests for Down Syndrome.

Can Edwards' Syndrome be detected prenatally without relying on invasive testing methods? The answer is yes. While amniocentesis tests for Edwards' Syndrome are the traditional option, their risks are more than negligible. The NIPT screening kits developed by Eurofins Biomnis offer a detection rate of over 99%. This allows healthcare providers to frequently eliminate all need to undergo amniocentesis tests for Edwards' Syndrome. How does this work? The NIPT test quickly and accurately analyzes the maternal blood sample to detect whether a trisomy is present in the fetus: as a result, risk is minimized.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%